Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer - Wikidata - awgldk - TriplyDB

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

http://www.wikidata.org/entity/Q28293019

about

The detection, treatment, and biology of epithelial ovarian cancer Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer Beyond CA125: the coming of age of ovarian cancer biomarkers Mesothelin expression in the leptomeninges and meningiomas Mesothelin targeted cancer immunotherapy Clinical impacts of mesothelin expression in gastrointestinal carcinomas Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin Role of mesothelin in carbon nanotube-induced carcinogenic transformation of human bronchial epithelial cells Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.Linking the ovarian cancer transcriptome and immunome Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.Discovery of mesothelin and exploiting it as a target for immunotherapy.What's the place of immunotherapy in malignant mesothelioma treatments?Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.Antifouling surface layers for improved signal-to-noise of particle-based immunoassays.Mesothelin as a potential therapeutic target in human cholangiocarcinoma.Malignant peritoneal mesothelioma.Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.Identification of novel markers for the diagnosis of malignant pleural mesothelioma.Potential markers for detection and monitoring of ovarian cancer.Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors.Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma Autoantibodies to mesothelin in infertility.Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.Identifying molecular markers for the early detection of pancreatic neoplasia.Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers.Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.

P2860

Q21198791-043F14F1-0911-436B-A20B-E45890237809 Q24651062-DFA51F60-345D-4CFF-A655-197E2CC0CF69 Q24651567-73E570A8-5A21-43E3-A981-83611E35C45E Q24654033-32D0D6F3-8362-4C4B-B547-2E5348FD07EF Q24656242-1B64CADA-D8C2-419B-B9EE-AC973D5B54F2 Q26748680-ED503D40-929D-40AB-8C19-3CA02D5786B9 Q26860736-89164229-EC08-40E1-A88B-FBABAA4BAD80 Q27015134-C5CB0E52-39BC-47BC-8BDF-2230C75660D7 Q27908595-C4D9DC15-607A-4CB5-B1F4-0E22F7615173 Q28254804-1EA9AAF6-B0E4-413D-B991-8B45D05BF89A Q28263206-BBB34DD0-BAF2-4F59-AE30-C426559831F4 Q28473512-D4E435DE-BA39-43B1-A60E-F944FB8BAA38 Q28547381-C1B748ED-F1DE-4D2B-8265-29A2A0351E46 Q28570727-0B27F4F7-DAB7-414C-A970-479EBF84F2B6 Q29248725-4BDDBBDE-F3C9-4326-90CC-423C6919E8A3 Q30478956-67A289D4-22ED-46D8-A73D-62E46E9B74F1 Q33313203-964DA438-7422-4D23-9CCA-DDA10208EA79 Q33503319-3C340C2B-2D25-4B9F-A1A3-CA5621DF4F28 Q33772688-3C4F5543-98AB-4054-BF38-CAC2AACFBCBC Q33781142-95BACAA5-07A2-4FEE-AF2E-71D3C05EA3F9 Q33828838-B72D21F4-D7B2-4A55-94F2-67C20A3EC8D1 Q33890558-D71E0A21-2E1A-48DD-9A11-A8F578690B24 Q33939569-346CDC1F-19BE-48CB-8921-D9E5E66C242E Q34167021-DF711F42-C3DA-48B6-9581-8812DC6EE3A4 Q34390899-12430CAE-8B7B-49C1-8232-38E89CB4D56A Q34614847-D5DADF79-6AC5-4B7A-884C-BBBDA862A7DA Q34676443-1B26761A-58E4-4BFB-A0DA-B52F6DEBD0A3 Q34760760-2A6F0118-904C-430E-BDDD-6535EB69F53B Q34960174-E88D1E63-55B7-44EB-9B1A-F1A4F4E02AEA Q34998586-2FEB6D6E-281A-43B9-B5F4-4A3FF9E03C2F Q35042668-22870E08-1AF7-4365-9C59-DC1CF7CD06F6 Q35185032-11725E07-C371-42D9-A12C-84EEB7702869 Q35552059-6C9712D5-A2B3-4A3C-9260-2AC59D17938E Q35802193-F1E74A5F-77D6-4F37-8FBB-1D37B64595AE Q35815574-E56A46BD-8FAC-46AE-BADF-F83E9829996E Q35832948-541B96DE-2320-42EE-82BB-CF27A0B5E4D9 Q36089304-E0DBDCB8-99E3-4F4D-AA30-7B47CE54610F Q36328508-D055A808-0A1C-4D22-9117-091F08BB3650 Q36623128-E965BE4E-7F69-4A01-BB44-9C276D4E39CF Q36639456-E3721DD2-34CF-428F-908E-E8CFD97F6FE5

P2860

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

http://www.wikidata.org/entity/Q28293019

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Detection and quantitation of ...... esothelioma and ovarian cancer

@ast

Detection and quantitation of ...... esothelioma and ovarian cancer

@en

Detection and quantitation of ...... esothelioma and ovarian cancer

@nl

type

label

Detection and quantitation of ...... esothelioma and ovarian cancer

@ast

Detection and quantitation of ...... esothelioma and ovarian cancer

@en

Detection and quantitation of ...... esothelioma and ovarian cancer

@nl

prefLabel

Detection and quantitation of ...... esothelioma and ovarian cancer

@ast

Detection and quantitation of ...... esothelioma and ovarian cancer

@en

Detection and quantitation of ...... esothelioma and ovarian cancer

@nl

P1433

Q28293019-6F279D8E-4497-4D2D-A34A-2014A06F9BED

P1476

Q28293019-4820EE0E-22E2-4AAC-BD76-D281DC912237

P2093

Q28293019-16CEBEFA-197F-4DDD-882F-A67D6BCBF40C

Q28293019-25FFCBEE-1CB1-4490-8A1F-F52F040EF92E

Q28293019-5E8F4449-1B49-4EAE-9C22-69FC237A6582

Q28293019-6C2E2007-10E9-4677-9643-D4E8EC1E941C

Q28293019-989DFB08-C9BE-4222-9E08-C58F6EC3FD8A

Q28293019-9B694C78-C59D-49C3-B6A3-0555A3D87C06

Q28293019-A6EFDAB0-0353-4BC5-A18D-30A62682C39A

Q28293019-BDF8DF28-E502-4F43-B163-EA9AAE923FC3

Q28293019-DA493296-F70A-47C0-9A9E-D4B46575B0AD

Q28293019-F6490803-4302-41C0-B012-00290BCA5E38

P304

Q28293019-CBA53B76-C0F8-45EF-8990-40A61454559F

P31

Q28293019-98203AC7-5994-4873-9B6D-72B7F958F220

P356

Q28293019-4E6D39F8-3E20-4595-896B-1C6AA925713B

P407

Q28293019-DE7A3D2A-2687-4AC0-98EE-65626E9BF3B1

P433

Q28293019-ECC050FC-A411-4A73-9B56-DFCC060A43D9

P478

Q28293019-7E302FA5-83A5-4FB0-9711-1A345CD49B2D

P577

Q28293019-AA3EA463-260E-41E5-86A2-936BF5E1CC54

P5875

Q28293019-9821CBF5-D28B-4A8F-9E52-2D0151D8F8FC

P698

Q28293019-7B00E975-9466-483A-A117-DE350DA337E7

P921

Q28293019-0CC9ADD1-D019-438D-B73F-EB11367D4CF1

Q28293019-B6A4B82B-FE18-4645-AF9D-C0297758C3D9

P356

1078-0432.CCR-05-1477

P1433

Clinical Cancer Research

P1476

Detection and quantitation of ...... esothelioma and ovarian cancer

@en

P2093

Alan T Remaley

http://www.w3.org/2001/XMLSchema#string

Derrick D Cox

http://www.w3.org/2001/XMLSchema#string

Ira Pastan

http://www.w3.org/2001/XMLSchema#string

James Pingpank

http://www.w3.org/2001/XMLSchema#string

Jingli Zhang

http://www.w3.org/2001/XMLSchema#string

Mark Willingham

http://www.w3.org/2001/XMLSchema#string

Masanori Onda

http://www.w3.org/2001/XMLSchema#string

Maureen L Sampson

http://www.w3.org/2001/XMLSchema#string

Raffit Hassan

http://www.w3.org/2001/XMLSchema#string

Richard Alexander

http://www.w3.org/2001/XMLSchema#string

P304

447-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-05-1477

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7345355

http://www.w3.org/2001/XMLSchema#string

P698

16428485

http://www.w3.org/2001/XMLSchema#string

P921